Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab as Frontline Treatment for Hodgkin Lymphoma Unsuitable for ABVD
NCT03331731Phase 2Completed
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Nov 2018
- Primary completion
- Feb 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in Hodgkin lymphoma (HL), sponsored by Peter MacCallum Cancer Centre. Primary endpoint: Objective Response Rate using Lugano Criteria. Started Nov 2018; status: completed.
02
Drugs
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT03331731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03331731.